Resources
8 Results (showing 1 - 8)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Mt. Vernon Square Room on Wednesday, March 4, 2020, at 2:45 PM
Posted 7/26/2023 (updated 3/28/2024)
Sonoran Prevention Works (SPW) shared some of its experiences implementing harm reduction in Cochise County, one of the more rural counties in AZ. SPW provides street-based outreach, testing, and peer support; offers training, education, and technical assistance and TA; and engages in local and state advocacy work.
Posted 7/26/2023 (updated 3/28/2024)
Health care workforce shortages continue to persist across rural communities, while current emerging trends have made it increasingly challenging to recruit physicians and other health care professionals. HRSA shared how one rural workforce initiative, the Rural Residency Planning and Development (RRPD) Program, is increasing the rural physician pipeline. Featured RRPD grantees discussed how their programs are shaping the behavioral health workforce of the future.
Posted 7/26/2023 (updated 3/28/2024)
This session covered how primary prevention efforts fit within each of the various stages of the Continuum of Care Model. Attendees learned how to (1) engage community stakeholders from each of the 12 sectors and (2) evidence-based practices to not only inform, but to reduce stigma and to create open dialogue as it relates to SUD.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.
Posted 7/26/2023 (updated 3/28/2024)
RSV 2023: 9:00 - 10:45 a.m. Welcome and Keynote Address (Day 1)
Posted 6/7/2022 (updated 3/27/2024)
Stigma and bias among community members, health care providers, and even family members toward individuals with substance use disorder negatively affects the care provided to this population. Stigma prevents individuals from seeking treatment and continues to divide them from their families, their communities, and the evidence-based treatments available.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.